跳至主要内容
临床试验/NCT03173300
NCT03173300已完成不适用

Clinical and Basic Investigations Into Phosphomannomutase Deficiency (PMM2-CDG)

Glycomine, Inc.22 个研究点 分布在 9 个国家目标入组 139 人开始时间: 2018年1月8日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
139
试验地点
22
主要终点
Collect clinical and biological information in patients with CDG-PMM2

研究概览

简要总结

Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG)

This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia).

详细描述

Subjects enrolled in this natural history study will be thoroughly examined for signs and symptoms of PMM2-CDG. Medical history, physical examination, laboratory testing and imaging studies will be performed during a single consultation. Follow-up will occur every 3- 6 months at a minimum, depending on the standard of care at the investigator's institution as well as the clinical status of the individual patient. All medical procedures are routine. No new therapy is offered as part of this study, and no change in the patients routine therapy is dictated by this protocol. The International Co-Operative Ataxia Rating Scale (ICARS) is to be performed every 3 months as an optional assessment. No randomization will be performed.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Informed consent/assent by the patient and/or their legally authorized representative
  • Confirmed diagnosis of PMM2-CDG, based on enzymatic or molecular tests
  • Willing and able to adhere to study requirements described in the protocol and consent/assent documents

排除标准

  • Known or suspected differential diagnosis of any other known CDG (not PMM2-CDG)
  • Currently using investigational drug
  • Blood loss of ≥ 250 mL or donated blood within 56 days, or donated plasma within 7 days before study screening

结局指标

主要结局

Collect clinical and biological information in patients with CDG-PMM2

时间窗: up to 5 years

Growth parameter, organ function tests, developmental tests, standard laboratory tests, disease severity score according to Nijmegen Paediatric CDG Rating Scale (NPCRS)

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (22)

Loading locations...

相似试验